WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), announced that it will conduct a conference call and audio webcast today at 5:30 p.m. Eastern Standard Time to discuss the results of the Phase 2b clinical trial of AZD3480 in cognitive dysfunction in schizophrenia and provide an update regarding Targacept’s business outlook. Participants from Targacept will include J. Donald deBethizy, Ph.D., President and Chief Executive Officer, and Alan A. Musso, Vice President and Chief Financial Officer.
